Abstract:Construction of an optimal vaccine against tumors relies on the availability of appropriate tumor-specific antigens capable to stimulate CD4+ T helper cells (TH) and CD8+ cytolytic T cells (CTL). CTL are considered the major effectors of the anti-tumor adaptive immune response as they recognize antigens presented on MHC class I (MHC-I) molecules usually expressed in all cells and thus also in tumors. However, attempts to translate in clinics vaccination protocols based only on tumor-specific MHC-I-bound peptides have resulted in very limited, if any, success. We believe failure was mostly due to inadequate triggering of the TH arm of adaptive immunity, as TH cells are necessary to trigger and maintain the proliferation of all the immune effector cells required to eliminate tumor cells. In this review, we focus on a novel strategy of anti-tumor vaccination established in our laboratory and based on the persistent expression of MHC class II (MHC-II) molecules in tumor cells. MHC-II are the restricting elements of TH recognition. They are usually not expressed in solid tumors. By genetically modifying tumor cells of distinct histological origin with the MHC-II transactivator CIITA, the physiological controller of MHC-II gene expression discovered in our laboratory, stable expression of all MHC class II genes was obtained. This resulted in tumor rejection or strong retardation of tumor growth in vivo in mice, mediated primarily by tumor-specific TH cells as assessed by both depletion and adoptive cell transfer experiments. Importantly these findings led us to apply this methodology to human settings for the purification of MHC-II-bound tumor specific peptides directly from tumor cells, specifically from hepatocarcinomas, and the construction of a multi-peptide (MHC-II and MHC-I specific) immunotherapeutic vaccine. Additionally, our approach unveiled a noticeable exception to the dogma that dendritic cells are the sole professional antigen presenting cells (APC) capable to prime naïve TH cells, because CIITA-dependent MHC-II expressing tumor cells could also perform this function. Thus, our approach has served not only to select the most appropriate tumor specific peptides to activate the key lymphocytes triggering the anti-tumor effector functions but also to increase our knowledge of intimate mechanisms governing basic immunological processes.

MHC class II regulation of CD8+T cell tolerance and implications in autoimmunity and cancer immunotherapy

Inhibition of follicular T-helper cells by CD8 + regulatory T cells is essential for self tolerance

Suppression of Melanoma by Mice Lacking MHC-II: Mechanisms and Implications for Cancer Immunotherapy.

Generation and Regulation of CD8(+) Regulatory T Cells.

Qa-1 Restriction of CD8+ Suppressor T Cells

The change of T cell repertoire due to central tolerance determines the antigenic requirement and strategy for inducing effective anti-tumor CD8 T cell response (TUM2P.888)

MHC Class II Presentation in Autoimmunity

The Molecular Mechanisms Mediated by CD4~+CD25~+ Regulatory T Cells

The expression of MHC class II molecules on murine breast tumors delays T-cell exhaustion, expands the T-cell repertoire, and slows tumor growth

MHC Class Ia Empowers MHC Class Ib-restricted CD8+ T Cells with Strong Tumoricidal Capacity

Pivotal Roles of CD8+ T Cells Restricted by MHC Class I–like Molecules in Autoimmune Diseases

Deconstructing CTL-mediated autoimmunity through weak TCR-cross-reactivity towards highly abundant self-antigen

Mechanisms and Control of Regulatory T Cells in Cancer

Humanized Mice Reveal New Insights into the Thymic Selection of Human Autoreactive CD8+ T Cells

CIITA-Driven MHC Class II Expressing Tumor Cells as Antigen Presenting Cell Performers: Toward the Construction of an Optimal Anti-tumor Vaccine

Cellular and molecular signaling towards T cell immunological self-tolerance

Targeting MHC-I molecules for cancer: function, mechanism, and therapeutic prospects.

Abrogation of Self-Tolerance by Misfolded Self-Antigens Complexed with MHC Class II Molecules

MHC class II restricted neoantigen: A promising target in tumor immunotherapy

Targeting MHC-I Molecules for Cancer: Function, Mechanism, and Therapeutic Prospects

MHC Class Ib-restricted CD8+ T Cells Possess Strong Tumoricidal Activities.